Health Trials

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

ConditionsAMLALLMDSMPD Withou MyelofibrosisNHL or HLInherited Metabolic DisordersHemoglobinopathiesBone Marrow FailureHLH
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
AgeUp to 21
SponsorMemorial Sloan Kettering Cancer Center

About this trial

This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.

Eligibility criteria

Qualifiers

Known prior diagnosis of myelodysplasia (MDS) or myeloproliferative disorder (MPS).

Therapy-related AML (t-AML).

White cell count at presentation > 100,000.

Presence of extramedullary leukemia at diagnosis.

Disqualifiers

Inadequate performance status/ organ function.

Advanced metabolic disease (EBMT handbook).

Active CNS leukemic involvement.

Indolent NHL or Hodgkin lymphoma with progression of disease after most recent salvage chemotherapy.

Trial design

Treatments tested in this trial

  • Clofarabine
  • Fludarabine
  • Busulfan
  • Cyclosporine-A
  • Mycophenolate Mofetil
  • Cord Blood Graft

Treatment groups

31 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Memorial Sloan Kettering Cancer Center

Lead sponsor

Source ClinicalTrials.gov